Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of letrozole in advanced or recurrent hormone receptor positive endometrial cancer
2004-003886-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letrozole in endometrial cancer (EC), sponsored by Novartis. Primary endpoint: Clinical response rate. Started Nov 2006; status: completed.
02
Drugs
letrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2004-003886-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003886-34.